Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Phenyltoloxamine | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Phenyltoloxamine | hsa00190 | Oxidative phosphorylation | 4.83E-06 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Phenyltoloxamine | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | Phenyltoloxamine | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | Phenyltoloxamine | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Phenyltoloxamine | hsa00565 | Ether lipid metabolism | 3.94E-02 | 1 | Q8N661 | TMEM86B | More | | Phenyltoloxamine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Phenyltoloxamine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Phenyltoloxamine | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Phenyltoloxamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Phenyltoloxamine | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Phenyltoloxamine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Phenyltoloxamine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Phenyltoloxamine | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Phenyltoloxamine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Phenyltoloxamine | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | | Phenyltoloxamine | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Phenyltoloxamine | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Phenyltoloxamine | hsa03013 | RNA transport | 9.49E-07 | 14 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3, FXR1 | More | | Phenyltoloxamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Phenyltoloxamine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | Phenyltoloxamine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Phenyltoloxamine | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Phenyltoloxamine | hsa04064 | NF-kappa B signaling pathway | 1.90E-03 | 12 | O00463, P14778, P19174, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, P19875, Q06643 | TRAF5, IL1R1, PLCG1, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CXCL2, LTB | More | | Phenyltoloxamine | hsa04071 | Sphingolipid signaling pathway | 2.55E-03 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Phenyltoloxamine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Phenyltoloxamine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Phenyltoloxamine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Phenyltoloxamine | hsa04120 | Ubiquitin mediated proteolysis | 2.51E-03 | 6 | Q14145, Q13042, P62837, Q15751, O95071, P0CG47 | KEAP1, CDC16, UBE2D2, HERC1, UBR5, UBB | More | | Phenyltoloxamine | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Phenyltoloxamine | hsa04137 | Mitophagy - animal | 9.52E-03 | 2 | Q07817, P0CG47 | BCL2L1, UBB | More | | Phenyltoloxamine | hsa04145 | Phagosome | 1.62E-04 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Phenyltoloxamine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Phenyltoloxamine | hsa04213 | Longevity regulating pathway - multiple species | 4.41E-03 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Phenyltoloxamine | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | Phenyltoloxamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Phenyltoloxamine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Phenyltoloxamine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Phenyltoloxamine | hsa04610 | Complement and coagulation cascades | 1.91E-03 | 1 | P0C0L4 | C4A | More | | Phenyltoloxamine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Phenyltoloxamine | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Phenyltoloxamine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Phenyltoloxamine | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Phenyltoloxamine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.09E-07 | 15 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | | Phenyltoloxamine | hsa04657 | IL-17 signaling pathway | 3.33E-03 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Phenyltoloxamine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | Phenyltoloxamine | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | | Phenyltoloxamine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | Phenyltoloxamine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.42E-02 | 5 | P23528, P06396, O14494, P14598, P17252 | CFL1, GSN, PLPP1, NCF1, PRKCA | More | | Phenyltoloxamine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Phenyltoloxamine | hsa04672 | Intestinal immune network for IgA production | 1.62E-02 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Phenyltoloxamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Phenyltoloxamine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Phenyltoloxamine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Phenyltoloxamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Phenyltoloxamine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Phenyltoloxamine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Phenyltoloxamine | hsa04744 | Phototransduction | 2.80E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Phenyltoloxamine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Phenyltoloxamine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Phenyltoloxamine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Phenyltoloxamine | hsa04916 | Melanogenesis | 4.80E-02 | 4 | P0DP23, Q9UJU2, P17252, P04628 | CALM1, LEF1, PRKCA, WNT1 | More | | Phenyltoloxamine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Phenyltoloxamine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Phenyltoloxamine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Phenyltoloxamine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Phenyltoloxamine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Phenyltoloxamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Phenyltoloxamine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Phenyltoloxamine | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | | Phenyltoloxamine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Phenyltoloxamine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Phenyltoloxamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Phenyltoloxamine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | Phenyltoloxamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Phenyltoloxamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Phenyltoloxamine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Phenyltoloxamine | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Phenyltoloxamine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.96E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Phenyltoloxamine | hsa05132 | Salmonella infection | 2.93E-02 | 10 | P51617, Q9UJU2, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, LEF1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Phenyltoloxamine | hsa05133 | Pertussis | 3.51E-02 | 1 | P0C0L4 | C4A | More | | Phenyltoloxamine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Phenyltoloxamine | hsa05140 | Leishmaniasis | 4.74E-05 | 10 | O75015, P14598, P42224, P13765, O60603, P25963, P29350, P49006, Q16539, Q15080 | FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Phenyltoloxamine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Phenyltoloxamine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Phenyltoloxamine | hsa05146 | Amoebiasis | 4.70E-06 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | Phenyltoloxamine | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Phenyltoloxamine | hsa05152 | Tuberculosis | 5.68E-03 | 9 | Q13488, P0DP23, P48382, O60603, P10415, P13765, P01568, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, IRAK1 | More | | Phenyltoloxamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Phenyltoloxamine | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Phenyltoloxamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Phenyltoloxamine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Phenyltoloxamine | hsa05170 | Human immunodeficiency virus 1 infection | 1.24E-04 | 17 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, O00463, Q14643, P01568, P51617, O60603, P23528, P10415, Q93034, Q9Y6Q5, P20333 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, TRAF5, ITPR1, IFNA21, IRAK1, TLR2, CFL1, BCL2, CUL5, AP1M2, TNFRSF1B | More | | Phenyltoloxamine | hsa05202 | Transcriptional misregulation in cancer | 4.29E-03 | 15 | Q12778, Q15532, P14780, P27930, P14923, Q16548, P11215, Q13489, Q13077, P35226, P05164, P08246, Q9C0K0, Q13547, P12980 | FOXO1, SS18, MMP9, IL1R2, JUP, BCL2A1, ITGAM, BIRC3, TRAF1, BMI1, MPO, ELA2, BCL11B, HDAC1, LYL1 | More | | Phenyltoloxamine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Phenyltoloxamine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Phenyltoloxamine | hsa05205 | Proteoglycans in cancer | 1.39E-03 | 13 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P01375, P23588, P04628, Q13635, P22694, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, TNF, EIF4B, WNT1, PTCH1, PRKACB, CD63 | More | | Phenyltoloxamine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Phenyltoloxamine | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Phenyltoloxamine | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Phenyltoloxamine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Phenyltoloxamine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.15E-03 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Phenyltoloxamine | hsa05320 | Autoimmune thyroid disease | 8.64E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Phenyltoloxamine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Phenyltoloxamine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Phenyltoloxamine | hsa05323 | Rheumatoid arthritis | 2.00E-02 | 3 | Q13488, P10747, O60603 | TCIRG1, CD28, TLR2 | More | | Phenyltoloxamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Phenyltoloxamine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Phenyltoloxamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Phenyltoloxamine | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Phenyltoloxamine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | Phenyltoloxamine | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |